Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

Overview of attention for article published in Lancet Oncology, January 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 8 news stories from 6 outlets.

om det ges i kombination med dagens standardbehandling för icke-metastaserad kastrationsresistent prostatacancer (CRPC).

Independent blogger Dr Bishal Gyawali rounds up 2016's publications in oncology 2016 was an important year for me, as I started…

Share this article: Enzalutamide reduced the risk of disease progression by 56% in mCRPC patients.

Astellas Pharma Europe Ltd., a subsidiary of Tokyo-based Astellas Pharma Inc. (TSE:4503), has announced that results from the…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 4 additional news stories.